๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Shengyang
Clinical trial register · China

Clinical Trials in Shengyang, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to

Trials with a site in Shengyang

13 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
VBC117First-in-Human Trial of VBC117 in Participants With Advanced Malignant Solid Tumors
NCT07772934Advanced Solid Tumors
VelaVigo Bio Inc
Phase 1/2
260
Zhejiang, Zhengzhou, Changsha, Nanchang, Shengyang, Shanghai, Taiyuan
2026-08-24
By invitation
Predictive Efficacy of Fecal Calprotectin Assay by Magnetic Particle Chemiluminescence for Mucosal Healing in Moderate-to-Severe Ulcerative Colitis Patients Undergoing Initial Biologic Therapy๏ผˆPRECAL๏ผ‰
NCT07721441Ulcerative Colitis (UC)
Tang-Du Hospital
Observational
200
Beijing, Chongqing, Shenzhen, Wuhan, Nanjing, Shengyang, Qingdao, Xiโ€™an
2026-06-18
Recruiting
A Phase II Study of AMT-676 Combination Therapies in Advanced Colorectal Cancer
NCT07474727Colorectal Cancer
Multitude Therapeutics Inc.
Phase 2
180
Fuzhou, Nanning, Guangzhou, Harbin, Luoyang, Wuhan, Changsha, Shengyang
2026-04-29
Recruiting
IN10018 in Combination With RNK08954 for the Treatment of KRASG12D Mutation-Positive Locally Advanced or Metastatic Solid Tumors
NCT07441174Solid Tumor Cancer, PDAC
InxMed (Shanghai) Co., Ltd.
Phase 1/2
92
Beijing, Fuzhou, Guangzhou, Zhengzhou, Luoyang, Changsha, Nanjing, Shengyang
2026-02-28
Recruiting
Zorifertinib With Osimertinib for NSCLC With Meningeal Progression
NCT07361705Patients With Advanced Non-small Cell Lung Cancer With Meningeal Progression After Osimertinib Treatment
Alpha Biopharma (Jiangsu) Co., Ltd.
Phase 1
42
Beijing, Shengyang, Guangzhou, Henan, Shanxi
2026-01-31
Recruiting
Efficacy and Safety of QD202 in Participants With Acute Ischemic Stroke Undergoing Thrombolysis Excluding Endovascular Thrombectomy
NCT07581210Acute Ischemic Stroke
Shanghai QuietD Biotechnology Co., Ltd.
Phase 2
120
Meizhou, Luoyang, Nanyang, Changchun, Meihekou, Benxi, Fuxin, Shengyang
2025-10-14
Recruiting
Study of Oral EGFR Inhibitor DZD6008 Combined With Sunvozertinib in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN8)
NCT07079475Non-Small Cell Lung Cancer
Dizal Pharmaceuticals
Phase 1/2
220
Beijing, Guangzhou, Harbin, Changsha, Nanjing, Changchun, Shengyang, Jinan
2025-07-30
Recruiting
Direct Ischemic Conditioning for Endovascular Recanalization for Anterior Large Vessel Occlusion (DICER-aLVO)
NCT06940128Ischemic Stroke
General Hospital of Shenyang Military Region
Not applicable
120
Shengyang
2025-03-31
Active, closed
The Evaluation of Safety and Myopia Progression Control Using Novel Spectacle Lens
NCT05886348Myopia
HOYA Lens Thailand LTD.
Not applicable
249
Beijing, Guangzhou, Shanghai, Shengyang, Tianjin
2023-07-31
Active, closed
Phase I Study of HRS-3738 in Recurrent and Refractory Non-Hodgkin's Lymphoma and Multiple Myeloma
NCT05363800Recurrent and Refractory Non-Hodgkin's Lymphoma and Multiple Myeloma
Jiangsu HengRui Medicine Co., Ltd.
Phase 1
74
Zhengzhou, Shengyang, Hangzhou
2022-06-17
Active, closed
Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer
NCT05132075Non-Small Cell Lung Cancer
Novartis Pharmaceuticals
Phase 3
95
Fuzhou, Guangzhou, Harbin, Changsha, Shengyang, Jinan, Hangzhou, Beijing
2022-06-15
Active, closed
STOPS Trial: Total vs Subtotal Colectomy for Slow Transit Constipation
NCT05352074Slow Transit Constipation, Surgery
Third Military Medical University
Not applicable
252
Yuzhong, Lanzhou, Wuhan, Nanjing, Shengyang, Qingdao, Pudong, Xiโ€™an
2022-03-27
Active, closed
Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010]
NCT02486718Non-Small Cell Lung Cancer
Hoffmann-La Roche
Phase 3
1,280
Beijing, Guangzhou, Hangzhou, Hefei, Shanghai, Shengyang, Shenyang, Suzhou
2015-10-31
Rows per page Showing 1–13 of 13
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 24 September 2026. https://priyalifescience.com/clinical-trials-china/city/shengyang

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 13 of those studies with a site in Shengyang.

How many clinical trials are recruiting in Shengyang?

6 of the 13 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 1 have not yet opened recruitment, 5 are active but closed to new participants, and 1 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Shengyang), 13 studies
PhaseStudiesRecruitingShare
Not applicable3123.1%
Phase 1/23223.1%
Phase 12115.4%
Phase 22215.4%
Phase 32015.4%
Observational107.7%

Most active sponsors

Lead sponsors with the most studies (Shengyang)
Lead sponsorStudiesRecruiting
Alpha Biopharma (Jiangsu) Co., Ltd.11
Dizal Pharmaceuticals11
General Hospital of Shenyang Military Region11
Hoffmann-La Roche10
HOYA Lens Thailand LTD.10
InxMed (Shanghai) Co., Ltd.11
Jiangsu HengRui Medicine Co., Ltd.10
Multitude Therapeutics Inc.11
Novartis Pharmaceuticals10
Shanghai QuietD Biotechnology Co., Ltd.11
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.